Processa Pharmaceuticals, Inc. (NASDAQ:PCSA) CEO Purchases $69,760.00 in Stock

Processa Pharmaceuticals, Inc. (NASDAQ:PCSA) CEO George K. Ng purchased 87,200 shares of Processa Pharmaceuticals stock in a transaction dated Monday, January 27th. The shares were bought at an average price of $0.80 per share, for a total transaction of $69,760.00. Following the acquisition, the chief executive officer now owns 87,200 shares in the company, valued at approximately $69,760. This trade represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Processa Pharmaceuticals Trading Up 10.6 %

Shares of NASDAQ:PCSA opened at $0.65 on Friday. The business has a 50-day moving average price of $0.92 and a 200 day moving average price of $1.23. The company has a market capitalization of $2.14 million, a price-to-earnings ratio of -0.19 and a beta of 0.62. Processa Pharmaceuticals, Inc. has a 12-month low of $0.47 and a 12-month high of $3.31.

Processa Pharmaceuticals (NASDAQ:PCSA) last issued its quarterly earnings data on Wednesday, October 30th. The company reported ($1.03) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.00) by ($0.03). As a group, equities research analysts predict that Processa Pharmaceuticals, Inc. will post -4.05 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Separately, HC Wainwright reiterated a “buy” rating and set a $6.00 price target on shares of Processa Pharmaceuticals in a report on Thursday, December 5th.

Processa Pharmaceuticals Company Profile

Processa Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, develops chemotherapy drugs to improve the safety and efficacy of cancer treatment. Its drugs are modifications of existing FDA-approved oncology drugs resulting in an alteration of the metabolism and/or distribution of drugs while maintaining the existing mechanisms of killing the cancer cells.